ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2126

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity

Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Lena Bugge Nordberg, Till Uhlig, Tore Kvien, Espen Haavardsholm, Siri Lillegraven and Anna-Birgitte Aga, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway

Meeting: ACR Convergence 2023

Keywords: Disease Activity, Outcome measures, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Rheumatoid Arthritis Impact of Disease (RAID) is a patient-reported outcome measure (PROM) originating from a EULAR initiative. It might support patient-centred care and shared decision-making between patient and health care provider. RAID could be a useful tool in regular clinical settings and remote monitoring, and its association with disease activity is thus of interest. RAIDs performance with regard to flare is not known, and our aim was to explore its responsiveness and discriminative abilities with regard to flares in disease activity.

Methods: We used pooled data from the first 12 months of the two ARCTIC REWIND trials assessing tapering of TNFi and csDMARDs (ClinicalTrials.gov: NCT01881308) (Lillegraven et al, JAMA, 2021). Eligible participants had RA according to the ACR/EULAR 2010 criteria, were in sustained remission for ≥12 months on stable DMARDs with Disease Activity Score (DAS) remission combined with no swollen joints at inclusion. Patients were randomized to continued stable treatment or tapered treatment. Study visits were conducted every four months, if a flare was suspected between visits the patient was seen within a week. Flare was defined as a combination of DAS >1.6, a ≥0.6 units increase and minimum 2 swollen joints, or a flare could be recorded in consensus between patient and rheumatologist. We evaluated the median RAID (total score and components) at the last visit before flare, at the flare visit and first visit after flare in relation to the suggested ≤2 RAID threshold for patient acceptable symptom state (PASS), and assessed the changes between those visits using Wilcoxon signed-rank test. The discriminative accuracies of RAID (total score and components) with respect to flares were assessed using area under the ROC curve (AUC) analyses based on logistic regression models. For comparison, similar analyses were performed for patient global assessment (PGA), DAS and C-reactive protein (CRP).

Results: Of the 248 patients included, 159 (64%) were female. Mean (SD) age and disease duration were 56.1 (11.8) and 6.3 (5.7) years. For patients who experienced a flare the median (IQR) RAID score was 0.9 (0.3, 1.4) at last visit prior to flare with 86% of scores below the PASS threshold (Figure). At the flare visit median RAID was 2.6 (1.4, 5.6) with 70% of scores above the PASS. Similar changes were observed in DAS, PGA and CRP (Figure, Table). All seven RAID domains increased significantly at the flare visit (p-values < 0.001), with the largest increase in pain. AUC (95% CI) values were0.88 (0.83, 0.93) for RAID, 0.92 (0.87, 0.97) for PGA, 0.94 (0.90, 0.98) for DAS and 0.76 (0.69, 0.84) for CRP. The RAID components with highest and lowest discriminative accuracies were pain (0.91 (0.86 to 0.95)) and sleep (0.69 (0.59 to 0.79)).

Conclusion: Disease activity flares were associated with a significant increase in median RAID, supporting RAIDs ability to respond to flare. RAID and PGA discriminated well between flare and non-flare, hence both PROMs might contribute to identification of flare in a regular clinical setting as well as in remote monitoring of disease activity.

Supporting image 1

Supporting image 2


Disclosures: K. Holten: None; N. Sundlisæter: None; J. Sexton: None; L. Nordberg: None; T. Uhlig: Galapagos, 2, 6, Lilly, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; T. Kvien: AbbVie/Abbott, 1, 2, 6, Bristol-Myers Squibb(BMS), 5, Galapagos, 2, 5, Gilead, 2, grunenthal, 6, Janssen, 2, 6, Novartis, 5, Pfizer, 2, 5, sandoz, 2, 6, UCB, 2, 5, 6; E. Haavardsholm: AbbVie/Abbott, 2, Boehringer-Ingelheim, 2, Eli Lilly, 2, Gilead, 2, Pfizer, 6, UCB, 6; S. Lillegraven: Boehringer-Ingelheim, 5; A. Aga: AbbVie, 2, 6, Eli Lilly, 2, 6, Novartis, 2, 6, Pfizer, 2, 6.

To cite this abstract in AMA style:

Holten K, Sundlisæter N, Sexton J, Nordberg L, Uhlig T, Kvien T, Haavardsholm E, Lillegraven S, Aga A. Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/performance-of-the-rheumatoid-arthritis-impact-of-disease-raid-score-in-relation-to-flares-in-disease-activity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-the-rheumatoid-arthritis-impact-of-disease-raid-score-in-relation-to-flares-in-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology